Equities

Cipla Ltd

Cipla Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,496.95
  • Today's Change33.60 / 2.30%
  • Shares traded2.11m
  • 1 Year change+68.33%
  • Beta0.4559
Data delayed at least 15 minutes, as of Mar 28 2024 10:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cipla Limited is an India-based company, which is primarily engaged in the business of pharmaceuticals. The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The Company's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, the United States, South Africa, and Rest of the World. The Company has its network of manufacturing, trading and other incidental operations in India and International markets. The Company has approximately 47 manufacturing sites.

  • Revenue in INR (TTM)253.50bn
  • Net income in INR37.08bn
  • Incorporated1935
  • Employees26.62k
  • Location
    Cipla LtdMumbai CentralMUMBAI 400013IndiaIND
  • Phone+91 2 224826000
  • Fax+91 2 224826120
  • Websitehttps://www.cipla.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aurobindo Pharma Ltd278.95bn27.70bn637.94bn15.69k23.04--14.902.2947.2547.25475.59--------17,778,640.00--9.84--14.9255.2953.059.9213.06--23.89--8.335.978.54-27.21-4.4712.203.71
Lupin Ltd194.80bn17.91bn736.74bn18.97k41.26--26.193.7839.1939.19426.18--------10,268,360.00--0.2337--0.344364.9958.569.290.3673--6.89--470.261.441.04128.1511.35-0.7025-4.36
Torrent Pharmaceuticals Ltd104.74bn15.03bn880.16bn13.57k58.52--38.288.4044.4444.44309.68--------7,716,901.00--6.70--10.4874.1270.8414.3511.22--6.32--63.6213.0710.0960.2212.92-6.2225.74
Divi's Laboratories Ltd74.93bn13.83bn914.62bn16.95k66.12--52.1712.2152.1152.11282.31--------4,420,514.00--18.50--20.4859.2357.2118.4627.90------31.31-13.3114.70-38.4115.7611.5524.57
Mankind Pharma Ltd-100.00bn-100.00bn921.65bn18.47k------------------------------------------------12.44---10.58------
Zydus Lifesciences Ltd186.81bn29.56bn1.01tn23.03k34.49--27.465.4329.2129.38184.58--------8,113,133.00--7.92--12.6166.2160.1415.8112.89------20.5514.087.59-12.341.83-0.353211.38
Dr Reddy's Laboratories Ltd272.13bn52.28bn1.03tn24.83k19.63--15.433.77313.75313.751,633.13--------10,958,640.00--9.68--13.8170.5565.5319.2112.76--48.92--17.8414.5011.55106.9433.2311.3114.87
Cipla Ltd253.50bn37.08bn1.21tn26.62k32.60--24.904.7745.9245.92313.91--------9,524,760.00--8.61--10.6065.1657.9714.7711.17--47.26--19.054.558.3811.3314.717.7023.16
Data as of Mar 28 2024. Currency figures normalised to Cipla Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

19.53%Per cent of shares held by top holders
HolderShares% Held
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 15 Mar 202435.97m4.46%
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 202327.96m3.46%
Norges Bank Investment Managementas of 30 Jun 202323.86m2.96%
The Vanguard Group, Inc.as of 07 Mar 202420.04m2.48%
BlackRock Fund Advisorsas of 07 Mar 202414.36m1.78%
UTI Asset Management Co. Ltd. (Investment Management)as of 29 Feb 20248.94m1.11%
ICICI Prudential Asset Management Co. Ltd.as of 29 Feb 20247.93m0.98%
Kotak Mahindra Asset Management Co. Ltd.as of 29 Feb 20247.28m0.90%
Geode Capital Management LLCas of 20 Mar 20245.90m0.73%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 15 Mar 20245.41m0.67%
More ▼
Data from 31 Dec 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.